Meritage Pharma Reports Positive Phase 2b Data for Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis

Efficacy Parameter

Placebo N=18

Low Dose N=17

Medium Dose N=19

High Dose N=17

% Responders (Peak EOS =6/HPF + >50% Symptom Score Reduction) - p-value (OBS vs Placebo)

5.6 –

11.8 0.5282

52.6 0.0092

47.1 0.0174

% Subjects with Histologic Response (Peak EOS <6/HPF) - p-value (OBS vs Placebo)

5.6 –

23.5 0.1786

52.6 0.0090

94.1 0.0001

% Subjects with Histologic Remission (Peak EOS <1/HPF) - p-value (OBS vs Placebo)

0 –

11.8 0.4597

42.1 0.0042

76.5 <0.0001